Abstract
Agents that enhance T cell co-stimulatory signaling have emerged as promising cancer immunotherapies. Our laboratory has been evaluating the TNF receptor co-stimulatory molecule, OX40, which has the capacity to augment critical aspects of T cell function and induce tumor regression in animal models. Effective stimulation of OX40 expressing T cells was accomplished with agonist antibodies to OX40 that were eventually translated into a clinical trial for cancer patients. A recent attempt to assess the affect of immune senescence on OX40 therapy, revealed a dramatic loss of efficacy of the agonist therapy in older tumor-bearing mice. The deficiency in OX40-enhanced anti-tumor responses in older mice correlated with a decrease in the number of differentiated effector T cells. Further investigation suggests that the underlying age-related decline in the agonist OX40-mediated T cell responses was not inherent to the T cells themselves, but related to the host environment. Thus, effective use of immunotherapies based on T cell co-stimulatory molecules may require additional modifications, such as immune stimulants to increase innate immunity, to address age-related defects that reside outside of the T cell and within the host environment.
Similar content being viewed by others
References
Akiba H et al (2000) Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis. J Exp Med 191:375–380
Arch RH et al (2000) Translocation of TRAF proteins regulates apoptotic threshold of cells. Biochem Biophys Res Commun 272:936–945
Atanackovic D et al (2004) Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol 172:3289–3296
Brocker T et al (1999) CD4 T cell traffic control: in vivo evidence that ligation of OX40 on CD4 T cells by OX40-ligand expressed on dendritic cells leads to the accumulation of CD4 T cells in B follicles. Eur J Immunol 29:1610–1616
Cheever MA, Creekmore S (eds) (2007) National Cancer Institute agent workshop proceedings. http://web.ncifcrf.gov/research/brb/workshops.asp
Clise-Dwyer K et al (2007) Environmental and intrinsic factors lead to antigen unresponsiveness in CD4(+) recent thymic emigrants from aged mice. J Immunol 178:1321–1331
Coley WB (1891) Contribution to the knowledge of sarcoma. Ann Surg 14:199–220
Compaan DM, Hymowitz SG (2006) The crystal structure of the costimulatory OX40-OX40L complex. Structure 14:1321–1330
Croft M (2003) Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 3:609–620
Dominguez AL, Lustgarten J (2008) Implications of aging and self-tolerance on the generation of immune and antitumor immune responses. Cancer Res 68:5423–5431
Effros RB, Walford RL (1983) The immune response of aged mice to influenza: diminished T-cell proliferation, interleukin 2 production and cytotoxicity. Cell Immunol 81:298–305
Evans DE et al (2001) Engagement of OX40 enhances antigen-specific CD4(+) T cell mobilization/memory development and humoral immunity: comparison of alphaOX-40 with alphaCTLA-4. J Immunol 167:6804–6811
Ewel CH et al (1992) Polyinosinic–polycytidylic acid complexed with poly-l-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects. Cancer Res 52:3005–3010
Fujita T et al (2006) Functional characterization of OX40 expressed on human CD8+ T cells. Immunol Lett 106:27–33
Gough MJ et al (2008) OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Res 68:5206–5215
Gramaglia I et al (2000) The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J Immunol 165:3043–3050
Gramaglia I et al (1998) Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol 161:6510–6517
Grolleau-Julius A et al (2006) Effect of aging on bone marrow-derived murine CD11c+ CD4-CD8alpha-dendritic cell function. J Gerontol A Biol Sci Med Sci 61:1039–1047
Haynes L, Eaton SM (2005) The effect of age on the cognate function of CD4+ T cells. Immunol Rev 205:220–228
Kaleeba JA et al (1998) The OX-40 receptor provides a potent co-stimulatory signal capable of inducing encephalitogenicity in myelin-specific CD4+ T cells. Int Immunol 10:453–461
Kawamata S et al (1998) Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2- and TRAF5-mediated NF-kappaB activation. J Biol Chem 273:5808–5814
Kjaergaard J et al (2000) Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res 60:5514–5521
Krieg AM (2007) Development of TLR9 agonists for cancer therapy. J Clin Invest 117:1184–1194
Kuriyama H et al (2006) Mechanism of third signals provided by IL-12 and OX-40R ligation in eliciting therapeutic immunity following dendritic-tumor fusion vaccination. Cell Immunol 243:30–40
Lee SW et al (2006) Functional dichotomy between OX40 and 4–1BB in modulating effector CD8 T cell responses. J Immunol 177:4464–4472
Li SP et al (2002) Early antigen-specific response by naive CD8 T cells is not altered with aging. J Immunol 168:6120–6127
Linton PJ et al (1997) From naive to effector—alterations with aging. Immunol Rev 160:9–18
Linton PJ et al (2005) Intrinsic versus environmental influences on T-cell responses in aging. Immunol Rev 205:207–219
Lustgarten J et al (2004) Aged mice develop protective antitumor immune responses with appropriate costimulation. J Immunol 173:4510–4515
Maxwell JR et al (2000) Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion. J Immunol 164:107–112
Mittler JN, Lee WT (2004) Antigen-specific CD4 T cell clonal expansion and differentiation in the aged lymphoid microenvironment. I. The primary T cell response is unaffected. Mech Ageing Dev 125:47–57
Murata K et al (2002) Constitutive OX40/OX40 ligand interaction induces autoimmune-like diseases. J Immunol 169:4628–4636
Ohshima Y et al (1997) Expression and function of OX40 ligand on human dendritic cells. J Immunol 159:3838–3848
Prins RM et al (2006) The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol 176:157–164
Redmond WL et al (2007) Defects in the acquisition of CD8 T Cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist. J Immunol 179:7244–7253
Ruby CE et al (2008) IL-12 is required for anti-OX40-mediated CD4 T cell survival. J Immunol 180:2140–2148
Ruby CE et al (2007) Anti-OX40 stimulation in vivo enhances CD8(+) memory T cell survival and significantly increases recall responses. Eur J Immunol 37:157–166
Ruby CE, Weinberg AD (2009) OX40-enhanced tumor rejection and effector T cell differentiation decreases with age. J Immunol 182:1481–1489
Salek-Ardakani S, Croft M (2006) Regulation of CD4 T cell memory by OX40 (CD134). Vaccine 24:872–883
Sharma S et al (2008) CpG-ODN but not other TLR-ligands restore the antitumor responses in old mice: the implications for vaccinations in the aged. Cancer Immunol Immunother 57:549–561
Shurin GV et al (2004) Regulation of dendritic cell expansion in aged athymic nude mice by FLT3 ligand. Exp Gerontol 39:339–348
So T, Croft M (2007) Cutting edge: OX40 inhibits TGF-beta- and antigen-driven conversion of naive CD4 T cells into CD25+ Foxp3+ T cells. J Immunol 179:1427–1430
Song A et al (2007) Cooperation between CD4 and CD8 T cells for anti-tumor activity is enhanced by OX40 signals. Eur J Immunol 37:1224–1232
Takeda I et al (2004) Distinct roles for the OX40—OX40 ligand interaction in regulatory and nonregulatory T cells. J Immunol 172:3580–3589
Trinchieri G (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3:133–146
Trinchieri G, Sher A (2007) Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 7:179–190
Valzasina B et al (2005) Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 105:2845–2851
Vu MD et al (2007) OX40 costimulation turns off Foxp3+ Tregs. Blood 110:2501–2510
Watford WT et al (2003) The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev 14:361–368
Watts TH (2005) TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 23:23–68
Weinberg AD et al (2000) Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol 164:2160–2169
Weinberg AD et al (2006) Anti-OX40 (CD134) administration to nonhuman primates: immunostimulatory effects and toxicokinetic study. J Immunother 29:575–585
Weinberg AD et al (1998) OX-40: life beyond the effector T cell stage. Semin Immunol 10:471–480
Weinberg AD et al (1999) Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J Immunol 162:1818–1826
Acknowledgments
The authors would like to thank Drs Walter Urba and Michael Gough for their critical reading of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is part of the Symposium in Writing on “Impact of Ageing on Cancer Immunity and Immunotherapy”.
Rights and permissions
About this article
Cite this article
Ruby, C.E., Weinberg, A.D. The effect of aging on OX40 agonist-mediated cancer immunotherapy. Cancer Immunol Immunother 58, 1941–1947 (2009). https://doi.org/10.1007/s00262-009-0687-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-009-0687-6